TransMedics quickly became the leader in liver, heart, and lung transplants, but its third-quarter earnings left the market worried. Here's why I believe its pullback in share price is an opportunity.
These three stocks are trading deeply below their 52-week highs, and analyst project them to see big increases in earnings and revenue over coming years.
Is this the buy-the-dip opportunity investors have been waiting for?
Being the leader in their respective markets could make these stocks top performers in the long run.
TransMedics Group TMDX is scheduled to report third-quarter 2024 results on Oct. 28, after market close.In the last reported quarter, the company’s adjusted earnings per share of 35 cents surpassed the...
Henry Schein, Inc. HSIC is scheduled to release third-quarter 2024 results on Nov. 5, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.23,...
Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell.The company posted adjusted earnings per share (EPS) of $3.11 in the last reported...
Both of these stocks should have plenty of room to run.
Penumbra, Inc. PEN is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company’s robust portfolio expansion looks promising. However, the impact...